Comparative analysis of marketed factor VIII products: recombinant products are not alike vis‐a‐vis soluble protein aggregates and subvisible particles. (11th May 2018)

• Record Type: Journal Article
• Authors: Anzengruber, J.; Lubich, C.; Prenninger, T.; Gringeri, A.; Scheiflinger, F.; Reipert, B. M.; Malisauskas, M.
• Is Part Of: Journal of thrombosis and haemostasis. Volume 16:Number 6(2018)
• Page Start: 1176
• Page End: 1181
• Publication Date: 2018-05-11
• Subjects: factor VIII -- hemophilia A -- protein aggregates -- protein stability -- recombinant proteins; Thrombosis -- Periodicals; Hemostasis -- Periodicals; Blood coagulation disorders -- Periodicals; 616.1
• DOI: 10.1111/jth.14125
• Languages: English
• ISSNs: 1538-7933

Abstract

Abstract : Essentials Aggregation is a critical quality attribute of protein therapeutics influencing immunogenicity. Aggregates and subvisible particles in 9 recombinant factor VIII (rFVIII) products were analyzed. Major differences in aggregate and particle concentrations were detected after reconstitution. rFVIII product quality determined aggregation propensity under use‐relevant stress. Summary: Background: Recombinant protein technologies have facilitated the development of novel factor VIII (FVIII) therapeutics with improved production efficiency, potency and half‐live, and a low risk of viral transmission. The increasing number of recombinant FVIII (rFVIII) products and information on their efficacy, safety and cost allow patients and healthcare professionals to adjust treatment to individual needs. Nonetheless, 20–32% of previously untreated patients with severe hemophilia A develop inhibitory antibodies to rFVIII following treatment. The root cause of the immunogenicity of rFVIII products is not well understood. Data for human interferon and human insulin products suggest that critical quality parameters such as soluble protein aggregates (SPAs) and subvisible particles (SVPs) influence the immunogenicity of protein therapeutics. Therefore, we analyzed SPA and SVP concentrations in commercially available rFVIII products and determined how these parameters change upon exposure of rFVIII products to relevant stress conditions. Objectives: Compare critical quality parameters such as SPA and SVP concentrations in rFVIII products under intended use and use‐relevant stress conditions. Methods: Nine rFVIII products (≥ 3 lots each) were analyzed by high‐performance liquid chromatography‐size exclusion chromatography (HPLC‐SEC) and flow cytometry‐based particle analysis. Results/conclusions: SPAs and SVPs were present at different concentrations in all freshly reconstituted rFVIII products: SPA concentrations ranged from 0.2% to 11.6%; SVPs were 0.7 × 10 6 to 114.0 × 10 6 / 1000 IU. Under use‐relevant stress conditions (agitation and shear stress) the products formed additional SPAs and SVPs to different degrees. The collected data indicate that product quality determines its propensity to form SVPs and SPAs, and highlights differences between marketed rFVIII products.